Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.74 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938630 | 0.88 | HRH4 (0.86) | HRH4HRH3HRH1KMT2AMEN1 | |
| SCHEMBL16599281 | 0.87 | HRH4 (0.72) | AKR1C3HRH4HRH3HRH1DRD3 | |
| SCHEMBL16598621 | 0.86 | HRH4 (0.75) | AKR1C3HRH4HRH3HRH1DRD3 | |
| SCHEMBL13174204 | 0.85 | AKR1C3 (1.00) | AKR1C3HRH4HRH3DRD3KMT2A | |
| Jnj-7777120 SCHEMBL29381532 | 0.85 | HRH4 (1.00) | HRH4HRH3HRH1KMT2A | |
| Jnj-7777120 SCHEMBL186434 | 0.85 | HRH4 (1.00) | HRH4HRH3HRH1KMT2A | |
| SCHEMBL13173662 | 0.82 | HRH4 (0.69) | AKR1C3HRH4HRH3HRH1DRD3 | |
| SCHEMBL16599390 | 0.82 | HRH4 (0.76) | HRH4HRH3HRH1KMT2AMEN1 | |
| SCHEMBL16598766 | 0.81 | KMT2A (0.73) | HRH4HRH3HRH1DRD3KMT2A | |
| SCHEMBL17954140 | 0.81 | KMT2A (0.73) | AKR1C3HRH4HRH3HRH1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20080102476-A1 | Analyzing Histamine H4 Receptor-Mediated Effects In Whole Blood | KARLSSON LARS | 2008-05-01 | — | — | US | disclosed |
| EP-1545596-A4 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-28 | — | — | EP | disclosed |
| CN-1694703-A | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-09 | — | — | CN | disclosed |
| EP-1551406-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1545596-A2 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | disclosed |
| US-20050085487-A1 | Heterocyclic compounds | CARRUTHERS NICHOLAS I (US) | 2005-04-21 | — | — | US | disclosed |
| US-6803362-B2 | ANTIHISTAMINES SUCH AS (5-CHLORO-1H-INDOL-2-YL)-(4-METHYL-PIPERAZIN-1-YL)-METHANONE, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC OR BRONCHODILATOR AGENTS AND/OR IMMUNOLOGY MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040132715-A1 | Method to treat allergic rhinitis | DUNFORD PAUL J (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004022061-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004021999-A2 | USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGY AND ASTHMA | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1373204-A2 | HETEROCYCLIC COMPOUNDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030207893-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2002072548-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | AR, NR5A1, CYP17A1 | AKR1C3 72/4885HRH4 481/4885HRH3 998/4885 |
| US-20040132715-A1 | Method to treat allergic rhinitis | HRH2, HRH4, HRH1 | AKR1C3 1665/4885HRH4 2/4885HRH3 5/4885 |
| US-20050085487-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | AKR1C3 1970/4885HRH4 1501/4885HRH3 3116/4885 |
| US-20030207893-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | AKR1C3 1970/4885HRH4 1508/4885HRH3 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.